Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 15;12(6):787.
doi: 10.3390/brainsci12060787.

Neurosurgical Clinical Trials for Glioblastoma: Current and Future Directions

Ashish H Shah  1   2 , John D Heiss  1
Affiliations
Review

Neurosurgical Clinical Trials for Glioblastoma: Current and Future Directions

Ashish H Shah et al. Brain Sci. .

Abstract

The mainstays of glioblastoma treatment, maximal safe resection, radiotherapy preserving neurological function, and temozolomide (TMZ) chemotherapy have not changed for the past 17 years despite significant advances in the understanding of the genetics and molecular biology of glioblastoma. This review highlights the neurosurgical foundation for glioblastoma therapy. Here, we review the neurosurgeon's role in several new and clinically-approved treatments for glioblastoma. We describe delivery techniques such as blood-brain barrier disruption and convection-enhanced delivery (CED) that may be used to deliver therapeutic agents to tumor tissue in higher concentrations than oral or intravenous delivery. We mention pivotal clinical trials of immunotherapy for glioblastoma and explain their outcomes. Finally, we take a glimpse at ongoing clinical trials and promising translational studies to predict ways that new therapies may improve the prognosis of patients with glioblastoma.

Keywords: blood–brain barrier opening; brain mapping; connection-enhanced delivery; glioblastoma; immunotherapy; radiotherapy; temozolomide; tissue-treating fields.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Schematic demonstrating new hybrid approaches for glioblastoma therapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Duffau H. A new philosophy in surgery for diffuse low-grade glioma (DLGG): Oncological and functional outcomes. Neurochirurgie. 2013;59:2–8. doi: 10.1016/j.neuchi.2012.11.001. - DOI - PubMed
    1. Duffau H. Resecting diffuse low-grade gliomas to the boundaries of brain functions: A new concept in surgical neuro-oncology. J. Neurosurg. Sci. 2015;59:361–371. - PubMed
    1. Kahn E., Lane M., Sagher O. Eloquent: History of a word’s adoption into the neurosurgical lexicon. J. Neurosurg. 2017;127:1461–1466. doi: 10.3171/2017.3.JNS17659. - DOI - PubMed
    1. Jelsma R., Bucy P.C. Glioblastoma multiforme: Its treatment and some factors effecting survival. Arch. Neurol. 1969;20:161–171. doi: 10.1001/archneur.1969.00480080061007. - DOI - PubMed
    1. Walker M.D., Strike T.A., Sheline G.E. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int. J. Radiat. Oncol. Biol. Phys. 1979;5:1725–1731. doi: 10.1016/0360-3016(79)90553-4. - DOI - PubMed

LinkOut - more resources